Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis
This study demonstrates that EFG is an effective and safe treatment for patients with VLOMG. EFG exhibits potential as an early, fast-acting treatment and may confer sustained clinical benefits in this patient population.
Authors
- Xinyan Guo
- Mingjin Yang (ORCID: https://orcid.org/0000-0001-5470-9187)
- Tianyu Ma (ORCID: https://orcid.org/0000-0002-2326-5760)
- Zhouao Zhang (ORCID: https://orcid.org/0009-0000-6253-6167)
- Xue Du (ORCID: https://orcid.org/0009-0006-1522-1094)
- Yong Zhang (ORCID: https://orcid.org/0000-0001-6422-8491)
- Xiaoyu Huang (ORCID: https://orcid.org/0000-0002-0993-6994)
- Tiancheng Luo (ORCID: https://orcid.org/0000-0002-8309-4158)
- Deliang Peng
- Zhouyi Wang (ORCID: https://orcid.org/0009-0002-8690-247X)
Institutions
- Xuzhou Medical College (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-17
- DOI
- https://doi.org/10.3389/fimmu.2025.1579859
- Citations
- 5
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 6.95
Funders
- Jiangsu Commission of Health
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- Xuzhou Medical University